Debiopharm Innovation Fund is thrilled to announce our recognition as one of the Top 10 European Digital Health Investors by Galen Growth in their 2024 HT50 Core Investors ranking. This acknowledgment underlines our commitment to driving the innovation of digital health with strategic investments and high-impact partnerships. Joining this valued list alongside leading names in the sector reaffirms our role as a transformative force in healthcare technology.
This recognition would not have been possible without the innovative contributions of our portfolio startups. As a matter of fact, this exciting news fell upon another great achievement within our portfolio: two of our invested companies, Genialis and VeriSIM Life, have been selected as winners of the 2024 Biotech Breakthrough Awards. These honors demonstrate important achievements in their respective areas of innovation: Genialis, as a pioneer in AI-powered precision medicine, and VeriSIM Life, as a leader in advanced drug development simulations, exemplifying the type of visionary talent and technological advances we seek to empower.
Being included in the HT50 Core Investors list motivates us to continue identifying and supporting visionary entrepreneurs who are redefining the future of Digital Health.